ArticleBMC research notes2025
The impact of initiating SGLT2 inhibitors on eGFR: a pilot study at a secondary hospital in Malaysia.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe purpose of this study was to evaluate the effect of sodium-glucose cotransporter 2 inhibitors on estimated glomerular filtration rate and serum creatinine among patients with type 2 diabetes mellitus and chronic kidney disease receiving treatment in a secondary hospital in Malaysia. The study also examined changes in blood glucose control following treatment. This work represents real-world data generated from routine clinical practice rather than from a controlled trial.
resultsA total of 76 patients were included. Serum creatinine showed a mild rise at three months after treatment initiation and subsequently stabilised at six and twelve months. Estimated glomerular filtration rate declined over one year, but the reduction was modest and remained below ten per cent. Blood glucose control improved, with mean glycated haemoglobin decreasing from baseline to the three-month assessment and remaining stable thereafter. No meaningful association was observed between changes in glycated haemoglobin and kidney function throughout the follow-up period. Overall, the findings indicate that kidney function stabilised after the early phase of treatment and that blood glucose levels improved following the introduction of sodium-glucose cotransporter 2 inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.